Sydney M Crago

Several companies working in the retina space have shared that they plan to release data at this year’s meeting in Fort Lauderdale, Florida.

At the ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Giulia Corradetti, MD about AMD.

Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation

Several presentations will provide research updates on various topics related to retinal vein occlusion (RVO).

As the annual ARVO conference draws closer, more companies have released information on presentations related to their pipeline and new data.

The intent of this extension is to assess potentially greater durability compared to aflibercept and will increase the statistical power of the study.

This initiative will provide a variety of tools to promote awareness and education, including some resources in both English and Spanish.

Akari Therapeutics, Ocuphire Pharma, and PharmAbcine are among the companies that have shared their plans for presentations the ARVO annual conference, being held in Seattle, Washington. More companies are expected to announce their presentations in the coming days.

The Vision Simulator shows disease progression and vision loss simulations for diabetic macular edema, diabetic retinopathy, AMD, XLRP, and achromatopsia.

Rising costs of metabolic agents, particularly those used in the treatment of diabetes, impacts patients and the medical systems, such as Medicare and Medicaid.

Through free, virtual webinars, the companies are working to bring clinical education to eye care professionals around the world.

The program will use OCT images to identify and monitor AMD in its early stages.

The company’s AI technology uses retinal imaging to assess potential health risks in patients.

The company created this new role as they see continued growth and room for more expansion.

The SAB additions include Usha Chakravarthy, MBBS, PhD; Allen Ho, MD, FACS, FASRS, and Frank Holz, MD, FEBO, FAVO.

The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.

Modern Retina’s interview with Aracelis Torres, PhD, MPH sheds light on how real-world insights empower researchers to see trends and develop new strategies, sometimes even new products, to meet the treatment needs of patients.

Age-related macular degeneration continues to be a key development area for many pharmaceutical companies as the work to develop new treatment options and present data in the first few months of the year.

Research around the globe is working not only to develop treatments for AMD, but also to determine risk factors for the disease to help prevent future cases.

Nicole Bajic, MD, from the Cole Eye Institute at Cleveland Clinic shares her insights in preparing patients for the 2024 solar eclipse on April 8, 2024.

A total solar eclipse will cross 15 states on April 8, 2024. Durga Borkar, MD, MMCi shares how to communicate eye safety tips and prepare to treat anyone who does present with solar retinopathy.

2024 is already bringing new research and insights to the forefront of retinal vein occlusion and providing new ways to consider retinal vascular health.

In this cohort of 3 adult patients, there was positive safety and efficacy data.

In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407

MCO-010 demonstrated a statistically significant improvement of best-corrected visual acuity (BCVA) at week 52.

Research estimates that the RVO market with see a compound annual growth rate of 11.9%.

After 3 loading doses, the patients were randomly assigned to receive EYP-1901 or continue to receive aflibercept at an 8-week dosing pattern for 32 weeks.

Advances in virtual reality and AI are helping those with AMD and low vision.